导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.39% | 1410/4773 |
| 近一周 | -1.05% | 1588/5465 |
| 近一月 | -3.72% | 2767/5421 |
| 近一季 | -9.00% | 3470/5231 |
| 近半年 | -4.74% | 2922/4920 |
| 近一年 | 8.89% | 1266/4394 |
| 近两年 | 77.94% | 878/2954 |
| 近三年 | 40.82% | 743/2253 |
| 成立以来 | 176.44% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.98% 1113/4961 |
19.61% 1285/5312 |
- - |
- - |
| 2025 | 32.76% 1163/4813 |
2.28% 1416/3635 |
2.04% 1933/4076 |
25.80% 1378/4524 |
1.12% 1514/4813 |
| 2024 | 6.80% 1721/3463 |
-2.74% 1420/2808 |
-5.50% 1735/3014 |
16.84% 1335/3129 |
-0.55% 1461/3463 |
| 2023 | -5.82% 781/2656 |
8.13% 490/2280 |
-4.08% 1039/2385 |
-4.77% 1218/2515 |
-4.64% 1124/2655 |
| 2022 | -18.56% 727/2207 |
-13.96% 879/1919 |
3.34% 1168/2016 |
-10.88% 457/2113 |
2.79% 834/2208 |
| 2021 | 17.96% 220/1822 |
-1.44% 493/1255 |
10.03% 499/1330 |
5.09% 293/1466 |
3.52% 424/1822 |
| 2020 | 25.02% 624/1250 |
-4.17% 341/1028 |
17.75% 363/1067 |
7.47% 780/1164 |
3.10% 944/1184 |
| 2019 | 28.00% 526/1092 |
33.02% 150/754 |
-10.33% 732/804 |
0.38% 521/850 |
6.91% 520/918 |
| 2018 | -32.24% 525/834 |
- - |
- - |
- - |
-12.85% 487/691 |
| 2017 | 1.87% 446/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.27% 353/605 |
- - |
- - |
- - |
- - |
| 2015 | 40.06% 46/575 |
- - |
- - |
- - |
- - |
| 2014 | 38.49% 133/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实中证500ETF VS. 长安沪深300非周期A(740101) |